fluconazole has been researched along with ceftazidime in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bizzarri, B; Bolasco, A; Carradori, S; D'Ascenzio, M; Mari, E; Polletta, L; Rivanera, D; Secci, D; Zicari, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bizzarri, B; Bolasco, A; Carradori, S; Lotti, LV; Mari, E; Rivanera, D; Secci, D; Zicari, A | 1 |
| Akdemir, A; Bizzarri, B; Bolasco, A; Caprara, F; Carradori, S; De Monte, C; Mari, E; Mollica, A; Rivanera, D; Secci, D; Zicari, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aktumsek, A; Bizzarri, B; Carradori, S; Chimenti, P; De Monte, C; Mari, E; Mollica, A; Rivanera, D; Secci, D; Zengin, G; Zicari, A | 1 |
| Chang, WQ; Hu, QW; Li, Y; Lou, HX; Sun, B; Zhang, M; Zheng, HB | 1 |
| Bizzarri, B; Carradori, S; D'Ascenzio, M; De Monte, C; Grande, R; Mari, E; Patsilinakos, A; Ragno, R; Rivanera, D; Sabatino, M; Secci, D; Zicari, A | 1 |
1 review(s) available for fluconazole and ceftazidime
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for fluconazole and ceftazidime
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Candida; Cell Survival; Chemistry Techniques, Synthetic; Hep G2 Cells; Humans; Hydrazines; Microbial Sensitivity Tests | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.
Topics: Antifungal Agents; Candida; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Hydrazines; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Thiazoles | 2013 |
Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
Topics: 14-alpha Demethylase Inhibitors; Anti-Bacterial Agents; Antifungal Agents; Candida; Chemistry Techniques, Synthetic; Drug Design; Drug Evaluation, Preclinical; Fungal Proteins; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Small Molecule Libraries; Sterol 14-Demethylase; Structure-Activity Relationship; Thiazolidines | 2016 |
Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
Topics: Antifungal Agents; Antioxidants; Candida; Chelating Agents; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Thiazolidines; Toxicity Tests | 2016 |
Synthesis of riccardin D derivatives as potent antimicrobial agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; Fungi; Microbial Sensitivity Tests; Molecular Structure; Phenyl Ethers; Stilbenes; Structure-Activity Relationship | 2016 |
Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
Topics: Antifungal Agents; Candida; Carbon-13 Magnetic Resonance Spectroscopy; Drug Screening Assays, Antitumor; Gram-Negative Bacteria; Gram-Positive Bacteria; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Proton Magnetic Resonance Spectroscopy; Quantitative Structure-Activity Relationship; Thiazolidines | 2017 |